Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy.

Brantley MA, Edelstein SL, King JM, Plotzke MR, Apte RS, Kymes SM, Shiels A
Eye (Lond). 2009 23 (3): 626-31

PMID: 18292785 · PMCID: PMC5531276 · DOI:10.1038/eye.2008.28

AIM - To determine whether there is an association between complement factor H (CFH) or LOC387715 genotypes and response to treatment with photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD).

METHODS - Sixty-nine patients being treated for neovascular AMD with PDT were genotyped for the CFH Y402H and LOC387715 A69S polymorphisms by allele-specific digestion of PCR products. AMD phenotypes were characterized by clinical examination, fundus photography, and fluorescein angiography.

RESULTS - Adjusting for age, pre-PDT visual acuity (VA), and lesion type, mean VA after PDT was significantly worse for the CFH TT genotype than for the TC or CC genotypes (P=0.05). Post-PDT VA was significantly worse for the CFH TT genotype in the subgroup of patients with predominantly classic choroidal neovascular lesions (P=0.04), but not for the patients with occult lesions (P=0.22). For the LOC387715 A69S variant, there was no significant difference among the genotypes in response to PDT therapy.

CONCLUSIONS - The CFH Y402H variant was associated with a response to PDT treatment in this study. Patients with the CFH TT genotype fared significantly worse with PDT than did those with the CFH TC and CC genotypes, suggesting a potential relationship between CFH genotype and response to PDT.

MeSH Terms (16)

Aged Aged, 80 and over Choroidal Neovascularization Complement Factor H Female Genotype Humans Macular Degeneration Male Middle Aged Phenotype Photochemotherapy Prognosis Proteins Treatment Outcome Visual Acuity

Connections (1)

This publication is referenced by other Labnodes entities: